ClinicalTrials.gg

Program

mesutoclax

Also written as “ICP-248”, “ICP-248+Orelabrutinib” and “Mesutoclax (ICP-248)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Lymphoma, Mantle-Cell · Hematologic Neoplasms · Lymphoma, B-Cell, Marginal Zone, led by InnoCare Pharma.

Furthest: phase 3, since Apr 6, 20248 company-led studies, 8 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma88 open or runningphase 3since Apr 6, 2024Jan 12, 2023Jun 2027phase 1 · NCT06656494

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2023First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05728658 · 191 planned · China
  2. Apr 2, 2024Phase 1 study in Mature B-cell MalignanciesNCT06351527 · 78 planned · United States, Puerto Rico, Ukraine
  3. Apr 6, 2024Phase 3 study in Hematologic NeoplasmsNCT06378138 · 226 planned · China
  4. Oct 21, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06656494 · 266 planned · United States, Australia, China
  5. Jul 15, 2025Phase 2 study in RecurrenceNCT07082686 · 75 planned · China
  6. Aug 17, 2026Phase 3 study in RecurrenceNCT07784101 · 280 planned · China
  7. Oct 19, 20262 phase 3 studiesNCT07896590, NCT07925190

Ahead

  1. Jun 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06656494
  2. Jun 25, 2027Primary completion: phase 1 study in Mature B-cell MalignanciesNCT06351527
  3. Dec 2027Primary completion: phase 2 study in RecurrenceNCT07082686
  4. Oct 2028Primary completion: phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT07896590

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07925190Leukemia, Myeloid, Acute · China3RecruitingDec 2029318
NCT07896590Lymphoma, B-Cell, Marginal Zone · China3Not yet recruitingOct 2028292
NCT07784101Recurrence · China3Not yet recruitingOct 2032280
NCT07082686Recurrence · China2RecruitingDec 202775
NCT06656494Leukemia, Myeloid, Acute · United States, Australia, China1RecruitingJun 2027266
NCT06378138Hematologic Neoplasms · China3RecruitingNov 25, 2030226
NCT06351527Mature B-cell Malignancies · United States, Puerto Rico, Ukraine1RecruitingJun 25, 202778
NCT05728658Hematologic Neoplasms · China1RecruitingAug 30, 2025191

How it is read

Names in the registry

  • “ICP-248”, 8 entries
  • “ICP-248+Orelabrutinib”, 3 entries
  • “Mesutoclax (ICP-248)”, 1 entry
  • “ICP-248 +Rituximab”, 1 entry
  • “ICP-248+Orelabrutinib+Rituximab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.